RMC No. 125-2022: Updated FDA List Deletes Certain COVID-19 Treatment Medicines from CREATE Act VAT Exemption

RMC No. 125-2022 updates the FDA VAT-exempt medicines list, deleting certain COVID-19 treatment medicines under the CREATE Act. Businesses selling, purchasing, importing, distributing, prescribing, or accounting for medicines used in COVID-19 treatment must immediately re-check the current FDA-published List of VAT-Exempt Medicines before treating those medicines as VAT-exempt. RMC No. 125-2022 makes a critical update […]

RMC No. 51-2022: Updated VAT-Exempt Medicines for COVID-19, Hypertension, and Cancer Under the CREATE Act

RMC No. 51-2022 updates the CREATE Act VAT-exempt medicine list for COVID-19, hypertension, and a corrected cancer medicine entry. Businesses dealing in covered medicines should immediately check whether their invoicing, VAT treatment, product master files, and pharmacy or distribution records reflect the latest VAT-exempt medicine list recognized for CREATE Act purposes. RMC No. 51-2022 confirms […]